Maggio Lindsay, Nicolau David P, DaCosta Melissa, Rouse Dwight J, Hughes Brenna L
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, and the Department of Pharmacy, Women and Infants' Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island; and the Center for Anti-infective Research & Development, Hartford Hospital, Hartford, Connecticut.
Obstet Gynecol. 2015 May;125(5):1205-1210. doi: 10.1097/AOG.0000000000000789.
To compare adipose tissue concentration among obese women receiving 2 g compared with 3 g of precesarean cefazolin prophylaxis.
This was a double-blind randomized controlled trial of women with singleton gestations and body mass indexes (BMIs) of 30 or greater at their first prenatal visit undergoing cesarean delivery at term. Women were randomly allocated, stratified by BMI, to receive 2 g or 3 g of cefazolin. Subcutaneous adipose tissue was harvested twice: before (opening) fascial incision and after (closing) fascial closure. The primary outcome was opening adipose tissue cefazolin concentration, measured by high-pressure liquid chromatography.
From April 2013 to July 2014, 58 women were enrolled, 57 included in the analysis: 28 in the 2-g group and 29 in the 3-g group. Baseline characteristics were similar between groups. Median opening adipose tissue concentration was similar between the 2-g and 3-g groups (9.4 [interquartile range 5.1-13.4] compared with 11.7 [interquartile range 7-18.3] micrograms/g, P=.12). The percentage of women with opening concentrations above 8 micrograms/g, the minimally inhibitory concentration of cefazolin for Staphylococcus species, was similar (61% compared with 72%, P=.35). All samples were above 2 micrograms/g, the minimally inhibitory concentration for Enterobacteriaceae. Closing adipose tissue concentrations and stratified analyses were consistent with the overall analysis.
In obese women undergoing cesarean delivery, prophylaxis with 3 g of cefazolin did not significantly increase adipose tissue concentration. Thus, our data do not support recommendations for 3-g dosing.
I.
比较接受2克与3克剖宫产头孢唑林预防性用药的肥胖女性的脂肪组织浓度。
这是一项双盲随机对照试验,纳入首次产前检查时体重指数(BMI)为30或更高的单胎妊娠女性,她们在足月时接受剖宫产。女性按BMI分层随机分配,接受2克或3克头孢唑林。皮下脂肪组织在筋膜切开前(切开)和筋膜缝合后(关闭)各采集一次。主要结局是通过高压液相色谱法测量的切开时脂肪组织头孢唑林浓度。
2013年4月至2014年7月,共纳入58名女性,57名纳入分析:2克组28名,3克组29名。两组基线特征相似。2克组和3克组切开时脂肪组织浓度中位数相似(9.4[四分位间距5.1 - 13.4]与11.7[四分位间距7 - 18.3]微克/克,P = 0.12)。切开时浓度高于8微克/克(头孢唑林对葡萄球菌属的最低抑菌浓度)的女性百分比相似(61%与72%,P = 0.35)。所有样本均高于2微克/克(肠杆菌科的最低抑菌浓度)。关闭时脂肪组织浓度及分层分析与总体分析一致。
在接受剖宫产的肥胖女性中,3克头孢唑林预防性用药并未显著增加脂肪组织浓度。因此,我们的数据不支持3克给药的建议。
I级